Advertisement
Screener

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Increase (Decrease) in Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

MATINAS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Accrued Liabilities

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Increase (Decrease) in Accrued Liabilities of -$230.74 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2018-11-09

  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-09-30 was -$181.26K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-06-30 was $477.37K, a 121.76% increase year-over-year.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-03-31 was -$526.85K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2017-12-31 was $160.48K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2017 was $159.36K, a 27.40% decline from fiscal 2016.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2016 was $219.52K.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2015 was -$285.05K, a 171.23% decline from fiscal 2014.
  • MATINAS BIOPHARMA HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2014 was $400.20K, a 13.42% decline from fiscal 2013.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accrued Liabilities 12 month
2018-09-30-$181.26K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$296.11K
derived: sum of 2 quarters · filed 2018-11-09
-$230.74K
10-Q · filed 2018-11-09
-$70.26K
derived: sum of 4 quarters · filed 2018-11-09
2018-06-30$477.37K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
-$49.48K
10-Q · filed 2018-08-09
$111.00K
derived: sum of 3 quarters · filed 2018-08-09
$88.18K
derived: sum of 4 quarters · filed 2018-11-09
2018-03-31-$526.85K
10-Q · filed 2018-05-09
-$366.37K
derived: sum of 2 quarters · filed 2018-05-09
-$389.19K
derived: sum of 3 quarters · filed 2018-11-09
-$173.92K
derived: sum of 4 quarters · filed 2018-11-09
2017-12-31$160.48K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$137.66K
derived: sum of 2 quarters · filed 2018-11-09
$352.93K
derived: sum of 3 quarters · filed 2018-11-09
$159.36K
10-K · filed 2018-03-16
2017-09-30-$22.82K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$192.45K
derived: sum of 2 quarters · filed 2018-11-09
-$1.12K
10-Q · filed 2018-11-09
-$112.73K
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30$215.26K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$21.70K
10-Q · filed 2018-08-09
-$89.91K
derived: sum of 3 quarters · filed 2018-08-09
$78.16K
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31-$193.57K
10-Q · filed 2018-05-09
-$305.18K
derived: sum of 2 quarters · filed 2018-05-09
-$137.10K
derived: sum of 3 quarters · filed 2018-05-09
-$53.08K
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31-$111.61K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$56.47K
derived: sum of 2 quarters · filed 2018-03-16
$140.49K
derived: sum of 3 quarters · filed 2018-03-16
$219.52K
10-K · filed 2018-03-16
2016-09-30$168.08K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
$252.09K
derived: sum of 2 quarters · filed 2017-11-14
$331.13K
10-Q · filed 2017-11-14
$338.13K
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30$84.02K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
$163.05K
10-Q · filed 2017-08-08
$170.05K
derived: sum of 3 quarters · filed 2018-03-16
$361.93K
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31$79.03K
10-Q · filed 2017-05-15
$86.03K
derived: sum of 2 quarters · filed 2018-03-16
$277.91K
derived: sum of 3 quarters · filed 2018-03-16
-$172.67K
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$198.88K
derived: sum of 2 quarters · filed 2018-03-16
-$251.70K
derived: sum of 3 quarters · filed 2018-03-16
-$285.05K
10-K · filed 2018-03-16
2015-09-30$191.88K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
-$258.70K
derived: sum of 2 quarters · filed 2016-11-14
-$292.05K
10-Q · filed 2016-11-14
-$254.85K
10-Q · filed 2015-11-10
-$261.94K
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30-$450.58K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15
-$483.93K
10-Q · filed 2016-08-15
-$453.81K
derived: sum of 3 quarters · filed 2016-08-15
2015-03-31-$33.35K
10-Q · filed 2016-05-13
-$3.24K
derived: sum of 2 quarters · filed 2016-05-13
2014-12-31$30.11K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
$400.20K
10-K · filed 2016-03-30
2014-09-30$370.09K
10-Q · filed 2015-11-10
2013-12-31$462.25K
10-K · filed 2015-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
Genprex, Inc. (GNPX)United States$0.003B-0.02
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
ORAGENICS INC (OGEN)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B